Dual engineered bacteria improve inflammatory bowel disease in mice
Applied Microbiology and Biotechnology · 2024-12 · 108 (1)
DOI: 10.1007/s00253-024-13163-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 13.05.2024. Verfasst von Yong-Qi Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Escherichia coli, Probiotics, Interleukin-10. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program, the National Key R&D Program of China.
Abstract (Originalsprache)
Currently, there are many different therapies available for inflammatory bowel disease (IBD), including engineered live bacterial therapeutics. However, most of these studies focus on producing a single therapeutic drug using individual bacteria, which may cause inefficacy. The use of dual drugs can enhance therapeutic effects. However, expressing multiple therapeutic drugs in one bacterial chassis increases the burden on the bacterium and hinders good secretion and expression. Therefore, a dual-bacterial, dual-drug expression system allows for the introduction of two probiotic chassis and enhances both therapeutic and probiotic effects. In this study, we constructed a dual bacterial system to simultaneously neutralize pro-inflammatory factors and enhance the anti-inflammatory pathway. These bacteria for therapy consist of Escherichia coli Nissle 1917 that expressed and secreted anti-TNF-α nanobody and IL-10, respectively. The oral administration of genetically engineered bacteria led to a decrease in inflammatory cell infiltration in colon and a reduction in the levels of pro-inflammatory cytokines. Additionally, the administration of engineered bacteria did not markedly aggravate gut fibrosis and had a moderating effect on intestinal microbes. This system proposes a dual-engineered bacterial drug combination treatment therapy for inflammatory bowel disease, which provides a new approach to intervene and treat IBD. Key points • The paper discusses the effects of using dual engineered bacteria on IBD • Prospects of engineered bacteria in the clinical treatment of IBD Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
- Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. zhouying@ecust.edu.cn.
- Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China. bcye@ecust.edu.cn.
- Institute of Engineering Biology and Health, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang…
Förderung
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
- the National Key R&D Program of China
- the China Postdoctoral Science Foundation
Zitieren
APA
Wu, Y. Q., Zou, Z. P., Zhou, Y., & Ye, B. C. (2024). Dual engineered bacteria improve inflammatory bowel disease in mice. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-024-13163-w
Vancouver
Wu YQ, Zou ZP, Zhou Y, Ye BC. Dual engineered bacteria improve inflammatory bowel disease in mice. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-024-13163-w
BibTeX
@article{Wu2024,
author = {Wu, Yong-Qi and Zou, Zhen-Ping and Zhou, Ying and Ye, Bang-Ce},
title = {Dual engineered bacteria improve inflammatory bowel disease in mice},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
volume = {108},
number = {1},
doi = {10.1007/s00253-024-13163-w}
}
EUVIMED